Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 50-59
DOI: 10.1111/dom.70198 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.10.2025. Verfasst von Brianna Sa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Mental Disorders, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders. A comprehensive literature search was conducted to identify studies evaluating the association between GLP‐1RAs and psychiatric outcomes. The electronic databases systematically searched were PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase and Web of Science. GLP‐1RAs are increasingly recognised for their potential neuropsychiatric effects beyond glycaemic control and weight loss. Findings suggest modest antidepressant effects, inconsistent associations with suicidality and potential therapeutic benefit in disorders of reward regulation. These findings are constrained by limited sample diversity, variability in outcome measures and the consistent underrepresentation of individuals with psychiatric comorbidities, factors that warrant targeted future research. This review highlights key findings on the neuropsychiatric effects of GLP‐1RAs. The heterogeneity among the studies in terms of dosing, clinical indications and baseline psychiatric status complicates interpretation, but preliminary evidence suggests modest antidepressant effects and potential therapeutic roles in eating and SUD. Concerns regarding suicidality remain unresolved. In schizophrenia, GLP‐1RAs provide clear metabolic benefits but have not demonstrated consistent effects on psychiatric symptomatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Psychiatry, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Brianna Sa
Zitieren
APA
Sa, B., Maristany, A., Subramaniam, A., Guillen, R., Buonocore, B., Smith, A., Oldak, S. E., & Padilla, V. (2026). Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence. Diabetes, Obesity and Metabolism, 28(1), 50-59. https://doi.org/10.1111/dom.70198
Vancouver
Sa B, Maristany A, Subramaniam A, Guillen R, Buonocore B, Smith A, et al. Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence. Diabetes, Obesity and Metabolism. 2026;28(1):50-59. doi:10.1111/dom.70198
BibTeX
@article{Sa2026,
author = {Sa, Brianna and Maristany, Anthony and Subramaniam, Ashwin and Guillen, Ryan and Buonocore, Brooke and Smith, Audrey and Oldak, Sean E and Padilla, Vanessa},
title = {Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {1},
pages = {50--59},
doi = {10.1111/dom.70198}
}
EUVIMED